Acoramidis clinical trials
Also written AG10 and ALXN2060.
How each study uses acoramidis is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the acoramidis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 10 Feb 2025 · Beyonttra · EMEA/H/C/006333 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Eidos Therapeutics, a BridgeBio company (11) · Alexion Pharmaceuticals, Inc. (3) · Bayer (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test acoramidis.
Studies
Open first, then newest update. How each study uses acoramidis is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisRecruitingPhase 4BayerNCT07298044Written as Acoramidis
- To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Not yet recruitingPhase 3Eidos Therapeutics, a BridgeBio companyNCT07116473Written as Acoramidis (AG10)
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruitingPhase 3Eidos Therapeutics, a BridgeBio companyNCT06563895Written as Acoramidis
- Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisRecruitingPhase 4Eidos Therapeutics, a BridgeBio companyNCT07695701Written as Acoramidis (AG10) oral tablet
- Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac BiomarkersRecruitingPhase 4Alexion Pharmaceuticals, Inc.NCT07306949Written as Acoramidis
- Open-Label Study of AG10 in Patients With CardiomyopathyTerminatedPhase 2Eidos Therapeutics, a BridgeBio companyNCT03536767Written as Acoramidis
- A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CMCompletedPhase 3Alexion Pharmaceuticals, Inc.NCT04622046Written as ALXN2060
- Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04958135Written as Acoramidis
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsActive, not recruitingPhase 3Eidos Therapeutics, a BridgeBio companyNCT04988386Written as Acoramidis (AG10)
- A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy SubjectsCompletedPhase 1Eidos Therapeutics, a BridgeBio companyNCT04769479Written as acoramidis
- Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10CompletedPhase 1Eidos Therapeutics, a BridgeBio companyNCT03294707Written as AG10 oral tablet
- Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)WithdrawnPhase 3Eidos Therapeutics, a BridgeBio companyNCT04882735Written as Acoramidis
- Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyWithdrawnPhase 3Eidos Therapeutics, a BridgeBio companyNCT04418024Written as AG10
- Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyCompletedPhase 3Eidos Therapeutics, a BridgeBio companyNCT03860935Written as acoramidis
- Study of AG10 in Amyloid CardiomyopathyCompletedPhase 2Eidos Therapeutics, a BridgeBio companyNCT03458130Written as AG10
Codes
What other systems call acoramidis · ClinicalTrials.gg INT002107
- MeSH (NLM) C000731204acoramidisConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) T12B44A1OEACORAMIDISConfirmed FDA, NLM, Wikidata
- Wikidata Q27451739acoramidisConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170791AcoramidisOne source FDA
- DrugBank DB17999One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731204 | acoramidis | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | T12B44A1OE | ACORAMIDIS | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27451739 | acoramidis | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170791 | Acoramidis | One source FDA |
| DrugBank | DB17999 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.